hypoxic cancer secretome induces pre-metastatic bone lesions lysyl oxidase 
tumour metastasis complex process involving reciprocal interplay cancer cells host stroma primary secondary sites strongly influenced microenvironmental factors hypoxia1 tumour-secreted proteins play crucial role interactions2- present strategic therapeutic potential metastasis breast cancer bone affects approximately % patients advanced disease renders largely untreatable6 specifically osteolytic bone lesions bone destroyed lead debilitating skeletal complications increased patient morbidity mortality67 molecular interactions governing early events osteolytic lesion formation currently unclear show hypoxia specifically associated bone relapse patients oestrogen-receptor negative breast cancer global quantitative analysis hypoxic secretome identified lysyl oxidase lox significantly associated bone-tropism relapse high expression lox primary breast tumours systemic delivery lox leads osteolytic lesion formation whereas silencing inhibition lox activity abrogates tumour-driven osteolytic lesion formation identify lox novel regulator nfatc1-driven osteoclastogenesis independent rank ligand disrupts normal bone homeostasis leading formation focal pre-metastatic lesions show lesions subsequently provide platform circulating tumour cells colonize form bone metastases study identifies novel mechanism regulation bone homeostasis metastasis opening opportunities novel therapeutic intervention important clinical implications 
